Information on cefditoren pivoxil overdosage in humans is not available. However, with other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. In acute animal toxicity studies, cefditoren pivoxil when tested at the limit oral doses of 5100 mg/kg in rats and up to 2000 mg/kg in dogs did not exhibit any health effects of concern.
Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cimetidine | The serum concentration of Cefditoren can be decreased when it is combined with Cimetidine. |
| Nizatidine | The serum concentration of Cefditoren can be decreased when it is combined with Nizatidine. |
| Ranitidine | The serum concentration of Cefditoren can be decreased when it is combined with Ranitidine. |
| Famotidine | The serum concentration of Cefditoren can be decreased when it is combined with Famotidine. |
| Methantheline | The serum concentration of Cefditoren can be decreased when it is combined with Methantheline. |
| Magnesium oxide | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide. |
| Sodium bicarbonate | The serum concentration of Cefditoren can be decreased when it is combined with Sodium bicarbonate. |
| Aluminum hydroxide | The serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide. |
| Calcium carbonate | The serum concentration of Cefditoren can be decreased when it is combined with Calcium carbonate. |
| Metiamide | The serum concentration of Cefditoren can be decreased when it is combined with Metiamide. |
| Roxatidine acetate | The serum concentration of Cefditoren can be decreased when it is combined with Roxatidine acetate. |
| Magaldrate | The serum concentration of Cefditoren can be decreased when it is combined with Magaldrate. |
| Magnesium hydroxide | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium hydroxide. |
| Magnesium trisilicate | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium trisilicate. |
| Magnesium carbonate | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium carbonate. |
| Lafutidine | The serum concentration of Cefditoren can be decreased when it is combined with Lafutidine. |
| Lavoltidine | The serum concentration of Cefditoren can be decreased when it is combined with Lavoltidine. |
| Bismuth subnitrate | The serum concentration of Cefditoren can be decreased when it is combined with Bismuth subnitrate. |
| Magnesium silicate | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium silicate. |
| Aluminium acetoacetate | The serum concentration of Cefditoren can be decreased when it is combined with Aluminium acetoacetate. |
| Hydrotalcite | The serum concentration of Cefditoren can be decreased when it is combined with Hydrotalcite. |
| Magnesium peroxide | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium peroxide. |
| Almasilate | The serum concentration of Cefditoren can be decreased when it is combined with Almasilate. |
| Aluminium glycinate | The serum concentration of Cefditoren can be decreased when it is combined with Aluminium glycinate. |
| Aloglutamol | The serum concentration of Cefditoren can be decreased when it is combined with Aloglutamol. |
| Niperotidine | The serum concentration of Cefditoren can be decreased when it is combined with Niperotidine. |
| Calcium silicate | The serum concentration of Cefditoren can be decreased when it is combined with Calcium silicate. |
| Aluminium phosphate | The serum concentration of Cefditoren can be decreased when it is combined with Aluminium phosphate. |
| Pantoprazole | The serum concentration of Cefditoren can be decreased when it is combined with Pantoprazole. |
| Rabeprazole | The serum concentration of Cefditoren can be decreased when it is combined with Rabeprazole. |
| Omeprazole | The serum concentration of Cefditoren can be decreased when it is combined with Omeprazole. |
| Lansoprazole | The serum concentration of Cefditoren can be decreased when it is combined with Lansoprazole. |
| Esomeprazole | The serum concentration of Cefditoren can be decreased when it is combined with Esomeprazole. |
| Dexlansoprazole | The serum concentration of Cefditoren can be decreased when it is combined with Dexlansoprazole. |
| Dexrabeprazole | The serum concentration of Cefditoren can be decreased when it is combined with Dexrabeprazole. |
| Sodium zirconium cyclosilicate | The serum concentration of Cefditoren can be decreased when it is combined with Sodium zirconium cyclosilicate. |
| Vonoprazan | The serum concentration of Cefditoren can be decreased when it is combined with Vonoprazan. |
| Probenecid | The serum concentration of Cefditoren can be increased when it is combined with Probenecid. |
| Foscarnet | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Foscarnet. |
| Mannitol | The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefditoren. |
| Tenofovir disoproxil | Cefditoren may increase the nephrotoxic activities of Tenofovir disoproxil. |
| Tenofovir alafenamide | Cefditoren may increase the nephrotoxic activities of Tenofovir alafenamide. |
| Tenofovir | Cefditoren may increase the nephrotoxic activities of Tenofovir. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Promethazine | Promethazine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxepin | Doxepin can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asenapine | Asenapine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Epinastine | Epinastine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefditoren. |
| Cyclosporine | The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefditoren. |
| Icosapent | The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefditoren. |
| Cefotiam | The risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Cefditoren. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefditoren. |
| Cefmenoxime | The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefditoren. |
| Cefmetazole | The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefditoren. |
| Indomethacin | The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefditoren. |
| Triamterene | The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefditoren. |
| Cefpiramide | The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefditoren. |
| Loracarbef | The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefditoren. |
| Cefalotin | The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefditoren. |
| Nabumetone | The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefditoren. |
| Ketorolac | The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefditoren. |
| Tenoxicam | The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefditoren. |
| Celecoxib | The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefditoren. |
| Cefotaxime | The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefditoren. |
| Tolmetin | The risk or severity of nephrotoxicity can be increased when Tolmetin is combined with Cefditoren. |
| Rofecoxib | The risk or severity of nephrotoxicity can be increased when Rofecoxib is combined with Cefditoren. |
| Fenoprofen | The risk or severity of nephrotoxicity can be increased when Fenoprofen is combined with Cefditoren. |
| Valdecoxib | The risk or severity of nephrotoxicity can be increased when Valdecoxib is combined with Cefditoren. |
| Diclofenac | The risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Cefditoren. |
| Sulindac | The risk or severity of nephrotoxicity can be increased when Sulindac is combined with Cefditoren. |
| Bacitracin | The risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Cefditoren. |
| Amphotericin B | The risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Cefditoren. |
| Cephaloglycin | The risk or severity of nephrotoxicity can be increased when Cephaloglycin is combined with Cefditoren. |
| Adefovir dipivoxil | The risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Cefditoren. |
| Pentamidine | The risk or severity of nephrotoxicity can be increased when Pentamidine is combined with Cefditoren. |
| Mefenamic acid | The risk or severity of nephrotoxicity can be increased when Mefenamic acid is combined with Cefditoren. |
| Naproxen | The risk or severity of nephrotoxicity can be increased when Naproxen is combined with Cefditoren. |
| Sulfasalazine | The risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefditoren. |
| Phenylbutazone | The risk or severity of nephrotoxicity can be increased when Phenylbutazone is combined with Cefditoren. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Cefditoren is combined with Meloxicam. |
| Carprofen | The risk or severity of nephrotoxicity can be increased when Carprofen is combined with Cefditoren. |
| Tacrolimus | The risk or severity of nephrotoxicity can be increased when Tacrolimus is combined with Cefditoren. |
| Etacrynic acid | The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Cefditoren. |
| Ceforanide | The risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Cefditoren. |
| Salicylic acid | The risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Cefditoren. |
| Acetylsalicylic acid | The risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefditoren. |
| Hydrochlorothiazide | The risk or severity of nephrotoxicity can be increased when Hydrochlorothiazide is combined with Cefditoren. |
| Balsalazide | The risk or severity of nephrotoxicity can be increased when Balsalazide is combined with Cefditoren. |
| Atazanavir | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Atazanavir. |
| Colistimethate | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Colistimethate. |
| Cefuroxime | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefuroxime. |
| Cefapirin | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefapirin. |
| Cefprozil | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefprozil. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Lumiracoxib. |
| Cefamandole | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefamandole. |
| Cefazolin | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefazolin. |
| Cefonicid | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefonicid. |
| Cefoperazone | The risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Cefoperazone. |